← All trials
NCT04718909
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 9, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jan 22, 2021
- Last posted
- Feb 10, 2021
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Medical UniversityLead sponsor
- Peking UniversityCollaborator
- Guangxi Medical UniversityCollaborator
- Guangzhou Medical UniversityStudy chair
- Nanchang UniversityCollaborator
- Southern Medical UniversityCollaborator
- Shenzhen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Jiangmen Central HospitalCollaborator
- Shantou UniversityCollaborator
- Yuebei People's HospitalCollaborator
- Zhaoqing Gaoyao People's HospitalCollaborator
- Jieyang People's HospitalCollaborator
- The First People's Hospital of Zhaoqing CityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.